The University of Hyderabad (UoH) and CSIR-Centre for Cellular and Molecular Biology (CCMB) in collaboration with VINS Bioproducts, have developed the first antidote against Covid-19 — Vincov-19 — and have successfully completed the Phase 2 clinical trials across multiple centres in India.
The antidote, Vincov-19, is now ready for market authorisation and for simultaneous phase 3 clinical trials. The Team was led by Krishnan H Harshan at CCMB and the UoH team was headed by Nooruddin Khan.
Maximum coverage
Phase 2 Clinical trials were conducted across multiple centres in India and included over 200 patients. They also included testing the antidote against the Omicron variant to ensure maximum coverage against the virus and its known mutations. In this phase, Vincov-19 was administered to patients with moderate severity of Covid-19. One group of patients was given it along with Standard of Care (SoC), and another group was given SoC only.
“Vincov-19 showed an excellent…
